Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. - Wikidata - awgldk - TriplyDB

Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

http://www.wikidata.org/entity/Q46154428

about

Human cytomegalovirus resistance to antiviral drugs How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients Antiviral drug resistance in human cytomegalovirus In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models Human cytomegalovirus: challenges, opportunities and new drug development The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments.An algorithmic approach to treatment of cytomegalovirus retinitis.Medical and virological aspects of ocular human immunodeficiency virus infection for the ophthalmologist.Resistance of human cytomegalovirus to antiviral drugs.How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.Changing patterns of HIV related ocular disease.Semen-specific genetic characteristics of human immunodeficiency virus type 1 env.Clinical uses of cidofovir.Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.Therapeutic developments in cytomegalovirus retinitis.Changing therapeutic paradigms in CMV retinitis in AIDS.Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma.Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Cytomegalovirus (CMV) resistance to antivirals.Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.Complete sequence and genomic analysis of rhesus cytomegalovirus Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease.Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patients Resistance of herpesviruses to antiviral drugs Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines.Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.

P2860

Q24556634-1D41397F-2A53-46B9-8197-982F6908CC17 Q28069489-07CB1C21-174C-41F1-83A6-53CEE4D00314 Q28203967-4CDEBAF7-8467-47BC-8341-B5B64CCE261E Q28344285-461F2E28-DD65-4374-B088-D8721E159C05 Q28368061-5648B210-97F5-4960-899D-730CF425C8A1 Q28371858-3196C7FA-42AC-43C2-98A0-0D44412F7203 Q28376935-811D4CE1-F6E4-4AA2-B306-0768A062E536 Q33400808-981870DD-B26A-435B-B3E0-0F2406020CB0 Q33569542-DE478F60-F214-4FCC-8476-E05389A4261D Q33569593-350D0316-44E1-4E9F-B2D7-B89DD9A40B68 Q33588911-615B9B67-8978-4EB2-A8E4-E90CD41FF235 Q33592427-C9FDCCD8-BFCD-411F-BB02-6E05B6C7F3C1 Q33661417-555C1AFA-F64F-4DC7-98C5-49C54AAD7B85 Q33696065-637B4F04-A966-4C97-8059-765D101570BE Q33696787-C830B65F-A4D8-431A-834B-E917ED017A22 Q33711640-0C56139C-2539-4FA6-A02A-CE4A1CE32C41 Q33717839-89D00793-1293-481D-9A5B-357CF2BCF02E Q33867391-226C746A-9A2A-4317-B970-5B6512931283 Q33977394-D0ECAD51-0DE6-4E18-9498-716609D1E558 Q33978966-1CBE8077-AA36-4767-A739-F83DB4C4F53D Q34074692-F5197629-C1F2-4893-A8E6-A3E2B01B7129 Q34181810-4C7341B0-1899-4D43-BD7D-C724E2674693 Q34195000-62580EE4-6CAB-4B51-9935-115474C1B1F3 Q34294838-3B2210AF-ABA1-462C-9FBA-753D78DCB57E Q34294851-B22A8048-623D-46CE-B3E0-AD12618DE903 Q34670354-99BCF30B-6EA3-4C05-98AF-7F55027CC8A7 Q34722194-3AD60FC5-1B5F-4644-8430-D8A337EC9561 Q34922240-CA7B7480-06D9-4B19-9A53-570168A88620 Q35020562-80FB49EA-8FDE-4DBE-9BD2-84A0C4EAE989 Q35113383-F4348792-7019-4F32-86B8-D8377B4C2FDB Q35114921-09C0F43E-8A5C-4296-961E-C17355EC1095 Q35120370-031D11FA-3F21-410C-BDDD-3FC4D94C471E Q35175290-72CFE536-43C1-4E88-84E2-226FD6A6246D Q35227779-0238D0E4-97A3-46C6-8DE3-A60E982D42E1 Q35447500-A45E516A-E6E4-47C2-B99F-9715078292EF Q35648048-344B6F6B-25C8-47E0-BCB9-7A9D842B648A Q35807437-F73352FC-714A-480C-AD5A-5B9DD04E3B54 Q35816311-34F9D16D-FA92-49BF-8BE0-C17D7904FA86 Q35874959-C3D64967-3D6E-4D26-90E7-1344A4944F44 Q35900369-40890860-36CD-400A-BF88-4E13FFB403A9

P2860

Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

http://www.wikidata.org/entity/Q46154428

description

1991 nî lūn-bûn

@nan

1991年の論文

@ja

1991年学术文章

@wuu

1991年学术文章

@zh

1991年学术文章

@zh-cn

1991年学术文章

@zh-hans

1991年学术文章

@zh-my

1991年学术文章

@zh-sg

1991年學術文章

@yue

1991年學術文章

@zh-hant

name

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@en

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@nl

type

label

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@en

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@nl

prefLabel

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@en

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@nl

P1433

Q46154428-978D10FF-AC66-4904-9347-2D6600D18B72

P1476

Q46154428-2BA63C68-485B-4755-B761-C6465BE1B594

P2093

Q46154428-1E2E3AD0-E7AB-4EEC-8214-FFF32B9A0B94

Q46154428-223533B3-9658-4F96-8222-11FD0E01741B

Q46154428-252A64D9-4ACE-4E2E-84C4-DC4CA37B9915

Q46154428-5527F621-6A8D-4BF8-BAC2-830882460493

Q46154428-66F9780E-5ADA-4D2A-B6DE-FFA3534E3461

Q46154428-6B90D8C2-7C1F-40C2-942D-16F46770B48A

Q46154428-72FBFA23-C732-4171-85B2-E0B240214448

Q46154428-763C6461-DBBA-4A80-AF9F-E60DB0891E89

Q46154428-9B306C33-C690-42E4-B1BF-4EB26958CE9D

Q46154428-A5F7AA40-10B2-49B8-B054-95F342880885

P304

Q46154428-F787665F-6CEC-49D0-B2EE-683A4C7CA227

P31

Q46154428-3A6424A5-C0C1-41CD-B2A4-6F89F7C772D6

P356

Q46154428-EC4EC5B1-DECF-4A87-A1C9-798035E5222B

P407

Q46154428-61EE8AB2-FCD8-4DB2-8A28-16886CCBB7A2

P433

Q46154428-92706FBE-5B14-4627-88EE-632C30B1EF5F

P478

Q46154428-73521765-8A73-460C-A1A6-8AFFE82DA442

P577

Q46154428-27305D6B-904A-42B0-A8A8-9FA0553E6E3A

P698

Q46154428-C62A6425-8765-435E-8F61-B13E73D11787

P921

Q46154428-23BB6C65-04CA-4A47-8EC7-B21C16E849CC

Q46154428-CA393B79-B6C4-4661-A5BF-6D89B72F92EE

P356

P1433

The Journal of Infectious Diseases

P1476

Prevalence of resistance in pa ...... ous cytomegalovirus infection.

@en

P2093

Buhles WC

http://www.w3.org/2001/XMLSchema#string

Busch DF

http://www.w3.org/2001/XMLSchema#string

Drew WL

http://www.w3.org/2001/XMLSchema#string

Follansbee SE

http://www.w3.org/2001/XMLSchema#string

Gordon SM

http://www.w3.org/2001/XMLSchema#string

Gullett J

http://www.w3.org/2001/XMLSchema#string

Matthews TR

http://www.w3.org/2001/XMLSchema#string

Mehalko SG

http://www.w3.org/2001/XMLSchema#string

Miner RC

http://www.w3.org/2001/XMLSchema#string

Owen WF Jr

http://www.w3.org/2001/XMLSchema#string

P304

716-719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/163.4.716

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P577

1991-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1849157

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus